Faisal Hamid, MD
Internal Medicine · Bellerose, NYNPI 1063791572
Payments from drug & device makers
Across 209 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$859
- Lilly USA, LLC$501
- Bayer$497
- AbbVie$373
- Amgen$351
- Otsuka America Pharmaceutical, Inc.$330
- plus $2K from 22 others
What the payments were for
- Food & beverage$4,493100%
- Education$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 45 | $859 |
| Lilly USA, LLC | 26 | $501 |
| Bayer | 21 | $497 |
| AbbVie | 16 | $373 |
| Amgen(2 entities) | 11 | $351 |
| Otsuka America Pharmaceutical, Inc. | 17 | $330 |
| Mallinckrodt Hospital Products Inc. | 12 | $237 |
| Novartis | 8 | $208 |
| Boehringer Ingelheim | 8 | $187 |
| Abbott | 5 | $121 |
| Exact Sciences | 5 | $120 |
| Pfizer | 7 | $112 |
| Phathom Pharmaceuticals, Inc. | 4 | $105 |
| Shield Therapeutics Inc | 3 | $67 |
| GSK | 3 | $59 |
| ANI Pharmaceuticals, Inc. | 2 | $51 |
| Renalytix AI, Inc. | 2 | $49 |
| Sanofi | 2 | $45 |
| Novo Nordisk | 2 | $34 |
| Akebia Therapeutics Inc | 1 | $29 |
| Evoke Pharma, Inc. | 2 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Vifor Pharma, Inc. | 1 | $22 |
| Ardelyx, Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Mallinckrodt Enterprises LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$125
How this compares
$4,497 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 93 | $123,448 |
| OzempicSemaglutide | 68 | $91,901 |
| FarxigaDapagliflozin Propanediol | 85 | $89,098 |
| JanuviaSitagliptin Phosphate | 58 | $61,427 |
| JanumetSitagliptin Phos/Metformin Hcl | 37 | $46,618 |
| TrulicityDulaglutide | 23 | $37,436 |
| MounjaroTirzepatide | 13 | $22,936 |
| Repatha SyringeEvolocumab | 20 | $22,577 |
| EliquisApixaban | 15 | $20,524 |
| KerendiaFinerenone | 17 | $19,593 |
| TradjentaLinagliptin | 13 | $17,498 |
| EntrestoSacubitril/Valsartan | 11 | $12,258 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $9,961 |
| DapagliflozinDapagliflozin Propanediol | 11 | $7,611 |
| Diclofenac Sodium | 53 | $6,744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $187 | $140,946106 claims |
| Novo NordiskOzempic | $34 | $91,90168 claims |
| AstraZenecaFarxiga | $859 | $89,09885 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $501 | $60,37236 claims |
| PfizerEliquis | $112 | $20,52415 claims |
| BayerKerendia | $497 | $19,59317 claims |
| NovartisEntresto | $208 | $12,25811 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $51 | $65931 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Bellerose
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.